TherapeuticsMD, Inc. Aktie News

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. („TherapeuticsMD" oder das "Unternehmen") (NASDAQ: TXMD), ein Unternehmen, das Rechte an Pharmaroyalty-Einnahmen hält, berichtete heute über die Finanzergebnisse für die drei Monate zum 30. Juni 2026. Finanzergebnisse für das zweite Quartal 2026 Nettoergebnis aus fortgeführten Geschäftsbereichen Das Nettoergebnis aus fortgeführten Geschäft...

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations totaled $103 thousand, compared to a ...

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted...